“The organization acts as an advocate for patients and the profession and by extension we are advocating for innovation,” Dr. Parke said.
AAO provides clinical guidelines for quality care and recently the IRIS registry, which is the first comprehensive eye disease clinical registry, has been providing great insights into real-world evidence from data derived from more than 75 million patient records from more than 18,000 physicians. It is an ideal database for glaucoma with data from over 5 million glaucoma patients and glaucoma suspects.
The extensive data provides the basis for forming policy and analyzing decisions. Dr. Parke concluded with the recognition that cost and innovation collide.
“It is our role as experts in the professional community and industry to help to try to reconcile and move the models forward,” he concluded. “Some market regulation always will be required and we will be moving to some form of value-based practice and the perfect value-based pricing has yet to be described. We are all going to benefit from more granular data on processes and outcomes so that we can get to a sustainable equilibrium that rewards innovation and ultimately moves our profession forward.”